NYSE:STE

STERIS Stock Forecast, Price & News

$212.52
-2.57 (-1.19 %)
(As of 09/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$210.70
$214.53
50-Day Range
$204.30
$225.82
52-Week Range
$164.19
$226.00
Volume506,361 shs
Average Volume613,090 shs
Market Capitalization$21.20 billion
P/E Ratio63.63
Dividend Yield0.80%
Beta0.56
30 days | 90 days | 365 days | Advanced Chart
Receive STE News and Ratings via Email

Sign-up to receive the latest news and ratings for STERIS and its competitors with MarketBeat's FREE daily newsletter.


STERIS logo

About STERIS

STERIS Plc engages in the provision of healthcare and life science product and service solutions. It operates through the following segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers portfolio of infection prevention, procedural, and gastrointestinal solutions. The Healthcare Specialty Services segment delivers solutions and managed services including hospital sterilization services and instrument, and scope repairs to acute care hospitals and other healthcare settings. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capitalequipment. The Applied Sterilization Technologies segment involves in contract sterilization and testing services for medical device and pharmaceutical manufacturer. The company was founded in 1985 and is headquartered in Dublin, Ireland.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.37 out of 5 stars

Medical Sector

199th out of 1,352 stocks

Surgical Appliances & Supplies Industry

6th out of 26 stocks

Analyst Opinion: 2.4Community Rank: 4.0Dividend Strength: 1.7Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











STERIS (NYSE:STE) Frequently Asked Questions

Is STERIS a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STERIS stock.
View analyst ratings for STERIS
or view top-rated stocks.

What stocks does MarketBeat like better than STERIS?

Wall Street analysts have given STERIS a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but STERIS wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is STERIS's next earnings date?

STERIS is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for STERIS
.

How were STERIS's earnings last quarter?

STERIS plc (NYSE:STE) announced its earnings results on Monday, August, 9th. The medical equipment provider reported $1.76 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.49 by $0.27. The medical equipment provider earned $968.40 million during the quarter, compared to the consensus estimate of $904.90 million. STERIS had a net margin of 8.39% and a trailing twelve-month return on equity of 12.81%. The firm's quarterly revenue was up 44.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.31 earnings per share.
View STERIS's earnings history
.

How has STERIS's stock been impacted by Coronavirus?

STERIS's stock was trading at $145.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, STE shares have increased by 46.3% and is now trading at $212.52.
View which stocks have been most impacted by COVID-19
.

How often does STERIS pay dividends? What is the dividend yield for STERIS?

STERIS declared a quarterly dividend on Monday, August 9th. Shareholders of record on Friday, September 3rd will be paid a dividend of $0.43 per share on Friday, September 24th. This represents a $1.72 dividend on an annualized basis and a yield of 0.81%. The ex-dividend date is Thursday, September 2nd. This is an increase from STERIS's previous quarterly dividend of $0.40.
View STERIS's dividend history
.

Is STERIS a good dividend stock?

STERIS pays an annual dividend of $1.72 per share and currently has a dividend yield of 0.80%. The dividend payout ratio of STERIS is 27.88%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, STERIS will have a dividend payout ratio of 19.84% next year. This indicates that STERIS will be able to sustain or increase its dividend.
View STERIS's dividend history.

What guidance has STERIS issued on next quarter's earnings?

STERIS issued an update on its FY 2022 earnings guidance on Monday, September, 6th. The company provided earnings per share (EPS) guidance of $7.600-$7.850 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.410. The company issued revenue guidance of $4.60 billion-$4.60 billion, compared to the consensus revenue estimate of $4.33 billion.

What price target have analysts set for STE?

6 brokers have issued 12 month target prices for STERIS's shares. Their forecasts range from $233.00 to $255.00. On average, they expect STERIS's share price to reach $242.40 in the next twelve months. This suggests a possible upside of 14.1% from the stock's current price.
View analysts' price targets for STERIS
or view top-rated stocks among Wall Street analysts.

Who are STERIS's key executives?

STERIS's management team includes the following people:
  • Daniel A. Carestio, President, Chief Executive Officer & Director
  • Michael Joseph Tokich, Chief Financial Officer & Senior Vice President
  • Kathleen Lynn Bardwell, Chief Compliance Officer & Senior Vice President
  • John Adam Zangerle, Secretary, Senior Vice President & General Counsel
  • Renato G. Tamaro, Treasurer & Vice President

What is Walter M. Rosebrough, Jr.'s approval rating as STERIS's CEO?

196 employees have rated STERIS CEO Walter M. Rosebrough, Jr. on Glassdoor.com. Walter M. Rosebrough, Jr. has an approval rating of 79% among STERIS's employees.

Who are some of STERIS's key competitors?

What other stocks do shareholders of STERIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STERIS investors own include Johnson & Johnson (JNJ), The Home Depot (HD), AT&T (T), Visa (V), AbbVie (ABBV), Abbott Laboratories (ABT), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA) and Medtronic (MDT).

What is STERIS's stock symbol?

STERIS trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."

Who are STERIS's major shareholders?

STERIS's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (12.57%), BlackRock Inc. (9.12%), WCM Investment Management LLC (8.03%), Massachusetts Financial Services Co. MA (4.87%), State Street Corp (4.05%) and APG Asset Management N.V. (4.02%). Company insiders that own STERIS stock include Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, David B Lewis, Jacqueline B Kosecoff, John Adam Zangerle, Julia Madsen, Karen L Burton, Mohsen Sohi, Renato Tamaro, Richard C Breeden, Richard Martin Steeves and Walter M Rosebrough Jr.
View institutional ownership trends for STERIS
.

Which major investors are selling STERIS stock?

STE stock was sold by a variety of institutional investors in the last quarter, including Great West Life Assurance Co. Can, Echo Street Capital Management LLC, Principal Financial Group Inc., Tekla Capital Management LLC, Millennium Management LLC, AQR Capital Management LLC, Los Angeles Capital Management LLC, and Frontier Capital Management Co. LLC. Company insiders that have sold STERIS company stock in the last year include Cary L Majors, Cynthia L Feldmann, David B Lewis, Jacqueline B Kosecoff, Julia Madsen, Karen L Burton, Renato Tamaro, and Walter M Rosebrough Jr.
View insider buying and selling activity for STERIS
or view top insider-selling stocks.

Which major investors are buying STERIS stock?

STE stock was bought by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Champlain Investment Partners LLC, Vanguard Group Inc., American Century Companies Inc., State Street Corp, Credit Suisse AG, Marshall Wace North America L.P., and Price T Rowe Associates Inc. MD.
View insider buying and selling activity for STERIS
or or view top insider-buying stocks.

How do I buy shares of STERIS?

Shares of STE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is STERIS's stock price today?

One share of STE stock can currently be purchased for approximately $212.52.

How much money does STERIS make?

STERIS has a market capitalization of $21.20 billion and generates $3.11 billion in revenue each year. The medical equipment provider earns $397.40 million in net income (profit) each year or $6.17 on an earnings per share basis.

How many employees does STERIS have?

STERIS employs 13,000 workers across the globe.

When was STERIS founded?

STERIS was founded in 1987.

What is STERIS's official website?

The official website for STERIS is www.steris.com.

Where are STERIS's headquarters?

How can I contact STERIS?

STERIS's mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The medical equipment provider can be reached via phone at (531) 232-2000 or via email at [email protected].


This page was last updated on 9/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.